An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer

BJU International

Volumn 96, Issue 3, 2005, Pages 334-339

  Attallah, Abdelfattah M ^a   Sakr, Hanem A ^b   Ismail, Hisham ^a   Abdel Hady, El Sayed K ^c   El Dosoky, Ibrahim ^b  

^a Biotechnology Research Center of New Damietta   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

^c Mansoura University   (Egypt)

Author keywords

52 kDa; Bladder; Diagnosis; dot ELISA; Follow up; Marker; NMP; Tumour; Urine

Indexed keywords

IMMUNOGLOBULIN G; NUCLEAR MATRIX PROTEIN; NUCLEAR MATRIX PROTEIN 52; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; URINALYSIS; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR MATRIX-ASSOCIATED PROTEINS; POINT-OF-CARE SYSTEMS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 23244441407     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05627.x     Document Type: Article

References (30)

1. El-Mawla NG, el-Bolkainy MN, Khaled HM. Bladder cancer in Africa - update. Semin Oncol 2001; 28: 174-8
2. Lopez VM, Galan JA, Fernandez-Suarez A et al. Usefulness of tissue polypeptide antigen in the follow-up of bladder cancer. Urology 2003; 62: 243-8
3. Clayman RV, Reddy P, Lange PH. Flexible fiberoptic and rigid-rod lens endoscopy of the lower urinary tract: a prospective controlled comparison. J Urol 1984; 131: 715-6
4. Walker L, Liston TGL, Loyd-Davies RW. Does flexible cystoscopy miss more tumours than rod-lens examination? Br J Urol 1993; 72: 449-50
5. Wiener HG, Vooijs GP, van't Hof-Grootenboer B. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol 1993; 37: 163-9
6. Simon MA, Lokeshwar VB, Soloway MS. Current bladder cancer tests: unnecessary or beneficial? Crit Rev Oncol Hematol 2003; 47: 91-107
7. Dey P. Urinary markers of bladder carcinoma. Clin Chim Acta 2004; 340: 57-65
8. Tinzl M, Marberger M. Urinary markers for detecting bladder cancer. EAU Update Series 2003; 1: 64-70
9. Getzenberg RH. The nuclear matrix and the regulation of gene expression: tissue specificity. J Cell Biochem 1994; 55: 22-31
10. Getzenberg RH, Coffey DS. Tissue specificity of the hormonal response in sex accessory is associated with nuclear matrix protein patterns. Mol Endo 1990; 4: 1336-42
11. Berezney RH, Coffey DS. Identification of a nuclear protein matrix. Biochem Biophys Res Commun 1974; 60: 1410-7
12. Partin AW, Getzenberg RH, Carmichael MJ et al. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 1993; 53: 744-6
13. Konety BR, Nangia AK, Nguyen T-ST et al. H. Identification of nuclear matrix protein alterations associated with renal cell carcinoma. J Urol 1998; 159: 1359-63
14. Khanuja PS, Lehr JE, Soule HD et al. Nuclear matrix proteins in normal and breast cancer cells. Concer Res 1993; 53: 3394-8
15. Keesee SK, Meneghini MD, Szaro RP, Wu YJ. Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci USA 1994; 91: 1913-6
16. Keesee SK, Meyer J, Marchese J et al. A nuclear matrix protein marker for cervical dysplasia. Proc Ann Meet Am Assoc Cancer Res 1998; 39: 202
17. McCaffrey JD, Gapany M, Faust RA, Davis AT, Adams GL, Ahmed K. Nuclear matrix proteins as malignant markers in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1997; 123: 283-8
18. Hughes JH, Cohen MB. Nuclear matrix proteins and their potential applications to diagnostic pathology. Am J Clin Pathol 1999; 111: 267-74
19. Laemmli UK. Cleavage of structure of proteins during assembly of the head of the bacteriophage T4. Nature 1970; 277: 680-5
20. Towbin H, Stachlin T, Gordou J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets; Procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4
21. Gordon MJ, Lee KJ, Arias AA et al. Protocol for resolving protein mixtures in CZE. Anal Chem 1991; 63: 69-72
22. Attallah AM, el-Didi M, Seif F et al. Comparative study between cytology and dot-ELISA for early detection of bladder cancer. Am J Clin Pathol 1996; 105: 109-14
23. Simon MA, Lokeshwar VB, Soloway MS. Current bladder cancer tests: unnecessary or beneficial? Crit Rev Oncol Hemotol 2003; 74: 91-107
24. Getzenberg RH, Konety BR, Oeler TA et al. Bladder cancer associated nuclear matrix proteins. Cancer Res 1996; 56: 1690-4
25. Konety BR, Nguyen TT, Dhir R et al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Concertes 2000; 6: 2618-25
26. Miyanaga N, Akaza H, Ishikawa S et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997; 31: 163-8
27. Friedrich MG, Hellstern A, Toma MI et al. Are false positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence? Europ Urol 2003; 43: 146-51
28. Lougue-Sorgho LC, Cisse R, Kagone M et al. Radiography and ultrasonography in the management of bladder tumors: 71 cases at the National Hospital Center of Yalgado Ouedraogo (Burkina Faso). Bull Soc Pathol Exot 2002; 95: 244-7
29. Herr HW, Shipley WU, Bajorin DF. Cancers of the genitourinary system. In DeVita VT, Hellman S, Rosenberg SA eds, Cancer: Principles and Practice of Oncology, 6th edn. Chapt 34-3, Philadelphia: Lippincott Williams Et Wilkins, 2001: 1396-418
30. Soloway MS, Briggman JV, Caprinito GA et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996; 156: 363-7